NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are ...

ATTENTION ESSA Pharma Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights ...

As the U.S. stock market reaches record highs amid an election-fueled rally, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, often seen as a ...

The company’s fifty day simple moving average is $5.59 and its two-hundred day simple moving average is $5.55. ESSA Pharma has a 52 week low of $1.40 and a 52 week high of $11.67. The stock has a ...

CinFina Pharma shared early-stage data for two of its Janssen-licensed obesity candidates. Johnson & Johnson‘s Darzalex hit ...

Fintel reports that on November 4, 2024, Oppenheimer downgraded their outlook for ESSA Pharma (NasdaqCM:EPIX) from Outperform ...

Piper Sandler analyst Joseph Catanzaro downgraded the rating on ESSA Pharma (EPIX – Research Report) to a Hold today, setting a price ...

Such findings raised questions about the added benefit of masofaniten, leading ESSA to abandon the drug’s development. In light of these results, Piper Sandler removed any projected value for ...

In a report released on November 1, Maury Raycroft from Jefferies downgraded ESSA Pharma (EPIX – Research Report) to a Hold, with a price ...

US clinical-stage firm ESSA Pharma has made the decision to terminate the Phase II clinical trial evaluating in a 2:1 ...

Fintel reports that on November 1, 2024, Jones Trading downgraded their outlook for ESSA Pharma (NasdaqCM:EPIX) from Buy to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...